Stockholm-based respiratory health startup NuvoAir is set to make its technology available in selected cystic fibrosis (CF) centres after entering a new partnership with Roche Italy. 

This marks NuvoAir’s first CF deal with a pharma company.

WHY IT MATTERS

According to the UK-based Cystic Fibrosis Trust, the genetic condition is estimated to affect around 100,000 people globally. It causes a build-up of sticky mucus in the lungs and in the digestive system, and symptoms include recurring chest infections, wheezing, coughing and shortness of breath.

NuvoAir’s platform has been developed for patients to conduct lung function assessments at home. They can use it to answer questionnaires that look at specific symptoms, track the progression of their disease, and share data with those caring for them.  

The hope is that NuvoAir's technology will reduce the need for in-person visits at clinics, and therefore help prevent infections.

THE LARGER TREND

In April last year, NuvoAir landed $3m in funding in a round led by Industrifonden, with participation from Investment AB Spiltan, to grow its team and enter new markets.

The startup faces stiff competition from a number of other players in the respiratory health space, including Propeller Health, which is known for its connected inhaler and was acquired by ResMed for $225m.

ON THE RECORD

“NuvoAir has developed a respiratory platform that has really the potential to support CF patients along their disease journey and optimise the workflow for the clinic,” Elia Ganzi, commercial excellence and established portfolio director at Roche, said. “This partnership is very strategic for us, because it is enabling a path of open innovation that positions Roche as a healthcare provider of integrated solutions and not just as a drug manufacturer,” Ganzi added.